Crystal structure of CX-4945 bound CK2 alpha from C. neoformans

5-[(3-chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic acid

Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.

MSGGRSVARVYANVNEKLGRSWWDYDNLVVQWGVQDNYEIVRKVGRGKYSEVFESIHLPTDSKCIVKVLKPVKKKKIKRE
IKILQNLAGGPNVVGLLDVVRDSQSKTPSIVTEYVNNTEFKTLYPKFSDFDVRYYIFELLKALDFCHSKGIMHRDVKPHN
VMIDHEKRTLRLIDWGLAEFYHPGTEYNVRVASRYFKGPELLVDFQEYDYSLDMWSLGCMFASMIFRKEPFFHGHDNADQ
LVKIAKVLGTDELYTYLERYDIDLDAQFDDILGRYPRKPWSRFVSSENQRYISSEAIDFLDKLLRYDHQERLTAEEAKEH
PYFEPVRQAAAQASASQP

Cryptococcus neoformans var. grubii Bt85
Escherichia coli 'BL21-Gold(DE3)pLysS AG'

0.2 M lithium sulfate, 0.1 M Tris pH 8.5, 30 %(w/v) PEG 4000, 30%(w/v) dextran sulfate sodium salt, 5 mM CX-4945

HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS